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ABSTRACT 
Objective: Rheumatoid arthritis (RA) patients have increased morbidity and mortality from premature cardiovascular (CV) disease (CVD). 
Framingham risk score (FRS) is a simplified coronary prediction tool developed to enable clinicians to assess the risk of a cardiovascular event and 
to identify candidate patients for risk factors modifications worldwide. The predictive ability of the FRS varies between populations, ethnic groups, 
and socio-economic status. The aim of this study is to find if there is any correlation between the Framingham risk score and the inflammatory and 
biochemical parameters used to measure disease activity and functional ability in Iraqi patients with active RA. 
Methods: A cross-sectional study was conducted in the rheumatology outpatient unit of Baghdad Teaching Hospital, from September 2012 to April 
2013. A total of 140 patients (40 males and 100 females) with active RA were involved in this study. Disease activity was measured by disease 
activity score of 28 joints (DAS28) and the simplified disease activity index (SDAI); whereas functional status of the patients were measured using 
The patient reported outcomes measurement information System (PROMIS HAQ) score. The FRS was calculated using a computerized formula from 
the web. Then the correlation between FRS with clinical parameters (DAS28, SDAI and PROMIS HAQ), plus the biochemical parameter (hsCRP, TNF 
and ESR) was determined.  
Result: There was a significant positive correlation between FRS and both of (DAS28 and SDAI). Additionally FRS was significantly correlated with 
each of (TNF, ESR and hsCRP). 
Conclusion: We found a significant correlation between FRS and the two most important methods used to measure disease activity (DAS28 and 
SDAI) but to obtain more significant result with other clinical parameter, long-term prospective studies with a larger sample size are needed.  
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INTRODUCTION 
Rheumatoid arthritis (RA) patients have increased morbidity and 
mortality from premature cardiovascular (CV) disease (CVD) [1].  
Immune dysregulation and systemic inflammation are believed to be 
integral to the development of accelerated atherogenesis in RA [2], 
and there are many parallels between the pathological and the 
immunological processes that occur in the synovium and the 
atheromatous lesions in the vessel walls [3]. 
Many RA severity markers such as autoantibody production (RF, 
anti-citrullinated peptide antibodies), markers of systemic 
inflammation (ESR, CRP, TNF, IL-6), number of inflamed joint, early 
functional decline and the presence of extra-articular features have 
all been reported to be strongly associated with adverse CV 
outcomes in RA [4,5]. 
Large longitudinal cohort studies performed in the 20th
The FRS is a simplified coronary prediction tool developed to enable 
clinicians to assess the risk of a cardiovascular event and to identify 
candidate patients for risk factor modifications worldwide [8].  
 century have 
discovered which factors are most adequately predict the risk for CV 
disease in the general population resulting in several CV risk 
estimation models, such as the Framingham Risk Score (FRS), the 
Reynolds Risk Score (RRS) and the Systematic Coronary Risk 
Evaluation (SCORE)[6,7].  
The predictive ability of the FRS varies between populations, ethnic 
groups, and socio-economic status [9].  
The aim of this study is to find if there was any correlation between 
the Framingham risk score and the inflammatory, clinical and 
biochemical parameters used to measure disease activity and 
functional ability in Iraqi patients with active RA. 
MATERIALS AND METHODS 
Study DESIGN 
A cross-sectional study was conducted in the rheumatology 
outpatient unit of Baghdad Teaching Hospital, from September 2012 
to April 2013. A total of 140 patients (40 males and 100 females) 
with active RA were involved in this study. Patients were diagnosed 
to have active RA by a rheumatologist. Ethical approval for research 
was obtained from the Ethics Committee of Baghdad University, 
College of Medicine, and Department of Medicine. Patients with 
diseases other than rheumatoid arthritis were excluded from 
participating in this study. 
Clinical and Laboratory Evaluation 
Disease activity was measured by disease activity score of 28 joints 
(DAS28) and the simplified disease activity index (SDAI) [10, 11]. 
The patients were clinically examined and swelling joints count (SJC) 
(0-28) and tender joints count (TJC) (0-28) were noted.  
The 28 joints included are bilateral knees, shoulders, elbows, wrists, 
metatarsophalangeal and proximal interphalangeal joints. The 
patients were asked to mark on the visual analogue scale (VAS) of 0-
10 cm according to their global assessment of pain. Erythrocytes 
sedimentation rate was measured by Westergren method [12], 
whereas high sensitive CRP and TNF are measured using enzyme 
linked immunosorbant assay ELISA technique [13, 14]. 
Framingham risk score (FRS) was calculated using a computerized 
formula from the web: http: //www. http: //cvdrisk. nhlbi. nih. gov/. 
It includes: age, gender, systolic blood pressure, smoking, total 
cholesterol (TC), high density lipoprotein (HDL) and whether or not 
the patient used antihypertensive drugs [15].  
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Systolic blood pressure was measured using a blood pressure 
monitor. TC and HDL were measured by colorimetric method using 
spectrophotometer [16, 17]. Other required information was taken 
directly from the patients. 
Disease activity score in 28 joint was calculated using an internet 
calculator: http: //www. das-score. nl/das28/ DAScalculators/ 
dasculators. html. The values > 2.6 and ≤ 3.2 were considered as low 
RA disease activity, values > 3.2 and ≤ 5.1 w ere considered as 
moderate disease activity and those > 5.1 were considered as high 
disease activity [18]; Whereas the SDAI was calculated by a direct 
summation of the five variables (SJC, TJC, VAS, EGA, and CRP) [11]. 
Simplified disease activity index value > 3.3 and ≤ 11 was considered 
as low RA disease activity, value > 11 and ≤ 26 was considered as 
moderate disease activity and those > 26 were considered as high 
disease activity [18].  
Assessment of functional ability were done by using The patient 
reported outcomes measurement information system questionnaire 
(PROMIS HAQ) which is a self-reported instrument comprised of 20 
items. Each item is scored from 0 (no difficulty) to 4 (unable to 
perform), The PROMIS HAQ score is the mean scores of the 20 items. 
It can be self-administered in five minutes and scored in less than 
one minute. It has been validated in numerous studies, is sensitive to 
change, and is widely used in observational studies and clinical trials 
[19]. Additionally morning stiffness of each patient was calculated 
according to patient approximate. 
Statistical Analysis 
All data were statistically analyzed using Statistical Package for the 
Social Sciences software version 16 (SPSS v.16). Pearson correlation 
coefficient was used to assess the correlation between continuous 
variables. All p values used were asymptotic and two sided. Values 
with p < 0.05 were considered significant. 
RESULTS 
The general demographic data for the 140 participated patients 
were elucidated in Table (1). While Table (2) showed the correlation 
between the Framingham risk score with RA disease activity, and 
other inflammatory and clinical parameters in RA patient.  
 
Table 1: Demographic data of patients 
Age (year) (mean±SD) 40.08 ± 10.9 
Female/male ratio 100/40 
Duration of RA (year) (mean±SD) 10.43 ± 7.09 
DAS28 (mean±SD) 5.67 ± 1.04 
SDAI (mean±SD) 25.9 ± 9.11 
Drug used ETN only number (%) 
MTX plus ETN number (%) 
80 (57.14) 
60 (42.86) 
RA=Rheumatoid arthritis; DAS28=Disease activity score of 28 Joints; 
SDAI= Simplified disease activity index; ETN= Etanercept; MTX= 
Methotrexate;  
 
Table 2: Correlation of the Framingham risk score with RA 
disease activity, and other inflammatory and clinical 
parameters in RA patient. 
Parameter R P. value 
Age 0.296 0.024* 
Proms HAQ 0.089 0.464 
SJC 0.121 0.364 
TJC 0.018 0.367 
VAS 0.143 0.316 
Mor. stiff 0.091 0.497 
DAS28 0.262 0.049* 
SDAI 0.303 0.025* 
ESR 0.294 0.025* 
CRP 0.314 0.016* 
TNF 0.269 0.041* 
Disease duration 0.082 0.541 
SJC= Swollen joint count; TJC=Tender joint count; VAS=Visual 
analogue scale; SDAI=Simplified disease activity index; 
DAS28=disease activity score of 28 joints; ESR=Erythrocyte 
sedimentation rate; CRP= C– reactive protein. (*) Correlation is 
significant at the 0.05 level (2-tailed). 
There is a significant positive correlation between the Framingham 
risk score and the inflammatory markers (ESR, TNF and CRP). 
Additionally FRS was significantly correlated with disease activity 
score DAS28, disease activity score SDAI and age. While other clinical 
markers and parameters (Proms HAQ, SJC, TJC, VAS, Mor. Stiff and 
disease duration) showed anon significant correlation with FRS. 
DISCUSSION 
This is the first study that try to collect the inflammatory, clinical 
and biochemical parameters; which are not included together in a 
single research before and to determine their relation to the risk 
of cardiovascular disease represented by (the Framingham risk 
score) in Iraqi patients, which may differ from other populations in 
epidemiological, socio economic and socio medical characteristic. 
This study showed a significant positive correlation between FRS 
and patient’s age plus many parameters that used to measure the 
functional disability and disease activity in Iraqi patients with RA 
like (DAS28, SDAI, ESR, CRP and TNF).  
This significant correlation between FRS and the age of the patients 
could be expected since it was demonstrated that the patients with 
RA with increasing age had a higher risk for CVDs, such as 
cardiovascular death, ischemic heart diseases, and heart failure [20] 
This study showed a significant correlation between FRS and disease 
activity scores (DAS28 and SDAI) which differ from another study 
made by Mustafa GـLER [21] that showed a statistically non 
significant correlation with DAS28. This difference can be explained 
since the two studies are differing in epidemiological and socio-
economic status of patients. 
High sensitive C reactive protein is a sensitive acute-phase protein 
that directly induces atherogenesis by disturbing endothelial 
function. In epidemiological studies, elevated levels of hsCRP are 
associated with an increased risk for CVD [22]. 
This study showed that FRS was significantly correlated with hsCRP 
and that consist with many other studies [23-25] 
Framingham risk score showed a significant correlation with TNF and 
ESR; (the two inflammatory parameter which have been shown to be 
associated with CVD in patients with RA and in the general population) 
[26-28]; and that consist with many other studies [26-28].  
Although patients with longer RA disease duration would be 
subjected to higher CV risk [29]; and a good correlation could be 
expected between FRS and RA disease duration but this study 
showed a non-significant correlation between FRS and disease 
duration and that can be attributed to the small sample size of this 
study.  
The non-significant correlation with other inflammatory clinical 
parameters like (PROMIS HAQ, SJC, TJC, morning stiffness) can be 
attributed to different reasons like small sample size and presence of 
other factors which not incorporated into FRS CV risk assessment 
tools which may affect cardiovascular risk other than inflammation; 
like the loss of function and muscle mass that commonly occurs after 
diagnosis of RA.  
Furthermore, therapies used to treat RA, such as corticosteroids, 
disease modifying anti-rheumatic medications and biologic response 
modifiers may have the disparate impact on CVD risk [30]. 
CONCLUSION 
we found a significant correlation between FRS and the two most 
important methods used to measure disease activity (DAS28 and 
SDAI) but to obtain more significant result with other clinical 
parameter or PROMIS-HAQ, long-term prospective studies with a 
larger sample size are needed. 
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